JP2017105793A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017105793A5 JP2017105793A5 JP2017006285A JP2017006285A JP2017105793A5 JP 2017105793 A5 JP2017105793 A5 JP 2017105793A5 JP 2017006285 A JP2017006285 A JP 2017006285A JP 2017006285 A JP2017006285 A JP 2017006285A JP 2017105793 A5 JP2017105793 A5 JP 2017105793A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- following formula
- pharmaceutical composition
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 1
- 108010002459 HIV Integrase Proteins 0.000 claims 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960003277 atazanavir Drugs 0.000 claims 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims 1
- 229960005107 darunavir Drugs 0.000 claims 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000366 emtricitabine Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 229960004525 lopinavir Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims 1
- 229960002814 rilpivirine Drugs 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883463P | 2013-09-27 | 2013-09-27 | |
| US61/883,463 | 2013-09-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516931A Division JP6081662B2 (ja) | 2013-09-27 | 2014-09-26 | Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017105793A JP2017105793A (ja) | 2017-06-15 |
| JP2017105793A5 true JP2017105793A5 (OSRAM) | 2017-09-07 |
| JP6550083B2 JP6550083B2 (ja) | 2019-07-24 |
Family
ID=52744477
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516931A Expired - Fee Related JP6081662B2 (ja) | 2013-09-27 | 2014-09-26 | Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体 |
| JP2017006285A Expired - Fee Related JP6550083B2 (ja) | 2013-09-27 | 2017-01-18 | Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516931A Expired - Fee Related JP6081662B2 (ja) | 2013-09-27 | 2014-09-26 | Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9861620B2 (OSRAM) |
| EP (1) | EP3049081B1 (OSRAM) |
| JP (2) | JP6081662B2 (OSRAM) |
| KR (2) | KR101809392B1 (OSRAM) |
| CN (1) | CN105744936B (OSRAM) |
| AP (1) | AP2016009157A0 (OSRAM) |
| AU (1) | AU2014324829B2 (OSRAM) |
| BR (1) | BR112016006651B8 (OSRAM) |
| CA (1) | CA2924829C (OSRAM) |
| CL (1) | CL2016000698A1 (OSRAM) |
| CR (1) | CR20160140A (OSRAM) |
| DO (1) | DOP2016000069A (OSRAM) |
| EA (1) | EA030695B1 (OSRAM) |
| EC (1) | ECSP16016726A (OSRAM) |
| ES (1) | ES2768658T3 (OSRAM) |
| GT (1) | GT201600056A (OSRAM) |
| HK (1) | HK1221648A1 (OSRAM) |
| IL (1) | IL244438B (OSRAM) |
| MA (1) | MA38922A3 (OSRAM) |
| MD (1) | MD4794B1 (OSRAM) |
| MX (1) | MX367057B (OSRAM) |
| NI (1) | NI201600040A (OSRAM) |
| PE (1) | PE20160501A1 (OSRAM) |
| PH (1) | PH12016500553A1 (OSRAM) |
| SA (1) | SA516370826B1 (OSRAM) |
| SG (1) | SG11201602217XA (OSRAM) |
| SV (1) | SV2016005171A (OSRAM) |
| TN (1) | TN2016000090A1 (OSRAM) |
| UA (1) | UA117499C2 (OSRAM) |
| WO (1) | WO2015048363A1 (OSRAM) |
| ZA (1) | ZA201601708B (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3067358T1 (sl) | 2012-12-21 | 2019-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
| AU2014286993B2 (en) | 2013-07-12 | 2018-10-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
| NO2865735T3 (OSRAM) | 2013-07-12 | 2018-07-21 | ||
| HK1221648A1 (zh) * | 2013-09-27 | 2017-06-09 | Merck Sharp & Dohme Corp. | 用作hiv整合酶抑制劑的取代喹嗪衍生物 |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| NO2717902T3 (OSRAM) | 2014-06-20 | 2018-06-23 | ||
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| WO2016027879A1 (ja) | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| WO2016154527A1 (en) * | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors |
| CA2980362C (en) | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| WO2016187788A1 (en) * | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
| US20190216725A1 (en) * | 2016-09-21 | 2019-07-18 | Merck Shapr & Dohme Corp. | Drug delivery system for the delivery of integrase inhibitors |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| US10786488B2 (en) | 2017-01-26 | 2020-09-29 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as HIV integrase inhibitors |
| JP2019016012A (ja) * | 2017-07-03 | 2019-01-31 | 東芝テック株式会社 | プリンタ装置及びプログラム |
| WO2019160783A1 (en) | 2018-02-15 | 2019-08-22 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| LT3805220T (lt) | 2018-05-31 | 2024-08-26 | Shionogi & Co., Ltd | Policikliniai karbamoilpiridono dariniai, skirti živ gydymui |
| SG11202011386QA (en) | 2018-05-31 | 2020-12-30 | Shionogi & Co | Polycyclic pyridone derivative |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| LT3833657T (lt) | 2019-07-31 | 2022-10-10 | Advanced Biodesign | Aminotiolesterų junginiai ir jų naudojimas |
| CN112521386B (zh) * | 2019-09-19 | 2023-05-26 | 周雨恬 | 具有抗病毒作用的多环吡啶酮化合物及其药物组合和用途 |
| JPWO2021107066A1 (OSRAM) | 2019-11-28 | 2021-06-03 | ||
| BR112022015771A2 (pt) | 2020-02-24 | 2022-10-11 | Gilead Sciences Inc | Compostos tetracíclicos para tratar a infecção por hiv |
| TW202222798A (zh) | 2020-09-30 | 2022-06-16 | 美商基利科學股份有限公司 | 橋接三環胺甲醯基吡啶酮化合物及其用途 |
| CA3202957A1 (en) | 2021-01-19 | 2022-07-28 | Hang CHU | Substituted pyridotriazine compounds and uses thereof |
| FR3119314B1 (fr) | 2021-01-29 | 2025-01-10 | Advanced Biodesign | Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025229179A1 (en) | 2024-05-03 | 2025-11-06 | Advanced Biodesign | Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000017197A1 (en) * | 1998-09-21 | 2000-03-30 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| DK2266958T1 (da) | 2001-08-10 | 2016-04-04 | Shionogi & Co | Antiviralt middel |
| SI1441735T1 (sl) | 2001-10-26 | 2006-06-30 | Angeletti P Ist Richerche Bio | N-substituirani hidroksipirimidinon-karboksamidniinhibitorji HIV-integraze |
| AU2002334205B2 (en) | 2001-10-26 | 2007-07-05 | Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase |
| EP1467970B1 (en) | 2002-01-17 | 2007-08-22 | Merck & Co., Inc. | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| EP1549315A4 (en) * | 2002-09-11 | 2007-05-23 | Merck & Co Inc | DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS |
| AU2003292437A1 (en) | 2002-12-27 | 2004-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors |
| US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| JP2006232849A (ja) * | 2003-08-13 | 2006-09-07 | Japan Tobacco Inc | 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| CN1930161A (zh) * | 2004-03-09 | 2007-03-14 | P·安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
| CA2558026C (en) | 2004-03-09 | 2010-12-14 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| WO2006033422A1 (ja) * | 2004-09-21 | 2006-03-30 | Japan Tobacco Inc. | キノリジノン化合物、およびそのｈｉｖインテグラーゼ阻害剤としての利用 |
| US7745459B2 (en) | 2004-09-21 | 2010-06-29 | Japan Tobacco Inc. | Quinolizinone compound and use thereof as HIV integrase inhibitor |
| US20060066414A1 (en) | 2004-09-28 | 2006-03-30 | Rockwell Scientific Licensing, Llc | Method and apparatus for changing the polarization of a signal |
| WO2006066414A1 (en) * | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| US7858788B2 (en) * | 2005-02-21 | 2010-12-28 | Shionogi & Co., Ltd. | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| JP5116660B2 (ja) | 2005-03-31 | 2013-01-09 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｈｉｖインテグラーゼ阻害剤 |
| PL3372281T3 (pl) * | 2005-04-28 | 2021-12-27 | Viiv Healthcare Company | Policykliczne pochodne karbamoilopirydonu o aktywności inhibitorowej wobec integrazy HIV |
| CN101212903B (zh) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物 |
| JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物 |
| US7494984B2 (en) | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| US7897592B2 (en) | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7902182B2 (en) | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007143446A1 (en) | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| EP2470014A4 (en) * | 2009-08-26 | 2013-01-16 | Merck Sharp & Dohme | HIV integrase inhibitors |
| AU2010305805B2 (en) | 2009-10-13 | 2014-04-03 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
| EA032868B1 (ru) | 2010-01-27 | 2019-07-31 | Вайв Хелткер Компани | Комбинация для лечения вич-инфекции |
| WO2011121105A1 (en) | 2010-04-02 | 2011-10-06 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| HK1221648A1 (zh) * | 2013-09-27 | 2017-06-09 | Merck Sharp & Dohme Corp. | 用作hiv整合酶抑制劑的取代喹嗪衍生物 |
-
2014
- 2014-09-26 HK HK16109802.1A patent/HK1221648A1/zh unknown
- 2014-09-26 PE PE2016000401A patent/PE20160501A1/es unknown
- 2014-09-26 EP EP14849935.3A patent/EP3049081B1/en active Active
- 2014-09-26 KR KR1020167010927A patent/KR101809392B1/ko not_active Expired - Fee Related
- 2014-09-26 WO PCT/US2014/057572 patent/WO2015048363A1/en not_active Ceased
- 2014-09-26 ES ES14849935T patent/ES2768658T3/es active Active
- 2014-09-26 KR KR1020177034018A patent/KR102102516B1/ko not_active Expired - Fee Related
- 2014-09-26 UA UAA201604645A patent/UA117499C2/uk unknown
- 2014-09-26 US US15/025,038 patent/US9861620B2/en active Active
- 2014-09-26 MA MA38922A patent/MA38922A3/fr unknown
- 2014-09-26 MX MX2016003860A patent/MX367057B/es active IP Right Grant
- 2014-09-26 MD MDA20160044A patent/MD4794B1/ro not_active IP Right Cessation
- 2014-09-26 JP JP2016516931A patent/JP6081662B2/ja not_active Expired - Fee Related
- 2014-09-26 CA CA2924829A patent/CA2924829C/en not_active Expired - Fee Related
- 2014-09-26 AU AU2014324829A patent/AU2014324829B2/en not_active Ceased
- 2014-09-26 CN CN201480064591.7A patent/CN105744936B/zh not_active Expired - Fee Related
- 2014-09-26 TN TN2016000090A patent/TN2016000090A1/en unknown
- 2014-09-26 EA EA201690669A patent/EA030695B1/ru not_active IP Right Cessation
- 2014-09-26 SG SG11201602217XA patent/SG11201602217XA/en unknown
- 2014-09-26 AP AP2016009157A patent/AP2016009157A0/en unknown
- 2014-09-26 BR BR112016006651A patent/BR112016006651B8/pt not_active IP Right Cessation
-
2016
- 2016-03-03 IL IL244438A patent/IL244438B/en active IP Right Grant
- 2016-03-11 ZA ZA2016/01708A patent/ZA201601708B/en unknown
- 2016-03-18 NI NI201600040A patent/NI201600040A/es unknown
- 2016-03-18 SV SV2016005171A patent/SV2016005171A/es unknown
- 2016-03-22 GT GT201600056A patent/GT201600056A/es unknown
- 2016-03-22 PH PH12016500553A patent/PH12016500553A1/en unknown
- 2016-03-23 DO DO2016000069A patent/DOP2016000069A/es unknown
- 2016-03-24 CL CL2016000698A patent/CL2016000698A1/es unknown
- 2016-03-27 SA SA516370826A patent/SA516370826B1/ar unknown
- 2016-03-28 CR CR20160140A patent/CR20160140A/es unknown
- 2016-04-25 EC ECIEPI201616726A patent/ECSP16016726A/es unknown
-
2017
- 2017-01-18 JP JP2017006285A patent/JP6550083B2/ja not_active Expired - Fee Related
- 2017-10-05 US US15/725,407 patent/US10201533B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017105793A5 (OSRAM) | ||
| JP2015078230A5 (OSRAM) | ||
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| JP2020504733A5 (OSRAM) | ||
| FI3692040T3 (fi) | Kemiallisia yhdisteitä | |
| JP2017186358A5 (OSRAM) | ||
| JP2016106149A5 (OSRAM) | ||
| JP2017509667A5 (OSRAM) | ||
| EP4616908A3 (en) | Oxysterols and methods of use thereof | |
| JP2014507446A5 (OSRAM) | ||
| JP2015038149A5 (OSRAM) | ||
| JP2020097577A5 (OSRAM) | ||
| HK1254343A1 (zh) | 药物制剂 | |
| JP2016530259A5 (OSRAM) | ||
| JP2017537066A5 (OSRAM) | ||
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| JP2013518107A5 (OSRAM) | ||
| JP2014221779A5 (OSRAM) | ||
| JP2016515561A5 (OSRAM) | ||
| MX381187B (es) | Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. | |
| JP2019500387A5 (OSRAM) | ||
| JP2018521020A5 (OSRAM) | ||
| JP2020500866A5 (OSRAM) | ||
| PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
| JP2017518982A5 (OSRAM) |